Clinical Trial Update: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of VIP152 in patients with advanced cancer has completed and an update has been issued.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• VIP152 (VIP152)

Snippet

Sponsor: Vincerx Pharma, Inc. | Conditions: Neoplasms | Phase 1 | Status: COMPLETED